Are low-intensity induction strategies better for older patients with acute myeloid leukemia?

详细信息	查看全文 | 推荐本文 |

• 作者：Gail J. Roboz^a ; ^{gar2001@med.cornell.edu} ; Usama Wissa^a ; Ellen K. Ritchie^a ; Usama Gergis^a ; Sebastian Mayer^a ; Joseph M. Scandura^a ; Paul J. Christos^b ; Eric J. Feldman^a
• 关键词：Leukemia ; Acute ; Myeloid ; Drug therapy ; Clinical trials ; Aged ; Remission induction
• 刊名：Leukemia Research
• 出版年：2012
• 期刊代码：186_01452126
• 类别：med
• 出版时间：April, 2012
• 卷：36
• 期：4
• 页码：407-412
• 文件大小：532 K

摘要

This study compares outcomes of low-intensity versus standard-intensity induction strategies for older patients with acute myeloid leukemia at the Weill Cornell Leukemia Program. From 1999 to 2009, 298 adults 鈮?0 years with AML underwent induction chemotherapy with low-intensity and standard-intensity regimens, based on physician and patient preferences and investigational protocol availability. Overall, 33%of the cohort achieved complete remission with initial treatment, 23%with low-intensity induction and 53%with standard-intensity induction (P < 0.0001). The median overall survival was 6.5 months and there was no significant difference in overall survival between patients initially treated with a low-intensity regimen compared to those receiving standard-intensity induction. There were no differences in 30- or 60-day mortality between the two groups.